cytisinicline + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Vaping

Conditions

Vaping, E-Cig Use

Trial Timeline

Jul 13, 2022 → Feb 28, 2023

NCT ID

NCT05431387

About cytisinicline + Placebo

cytisinicline + Placebo is a phase 2 stage product being developed by Achieve Life Sciences for Vaping. The current trial status is completed. This product is registered under clinical trial identifier NCT05431387. Target conditions include Vaping, E-Cig Use.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07392125	Phase 3	Recruiting	May 15, 2026	Sep 30, 2027	Vaping Cessation
NCT05431387	Phase 2	Completed	Jul 13, 2022	Feb 28, 2023	Vaping
NCT05206370	Phase 3	Completed	Jan 20, 2022	Mar 21, 2023	Smoking Cessation
NCT04576949	Phase 3	Completed	Oct 13, 2020	Dec 23, 2021	Smoking Cessation

Competing Products

1 competing product in Vaping

See all competitors

Product	Company	Stage	Hype Score
Cytisinicline + Placebo	Achieve Life Sciences	Phase 3	69

Other Products from Achieve Life Sciences

Custirsen + Docetaxel + Prednisone + DexamethasonePhase 3

Custirsen + DocetaxelPhase 3

Cytisinicline + PlaceboPhase 3

Taxol + TOCOSOL PaclitaxelPhase 3

Cytisinicline + PlaceboPhase 3